GRN1005 in Non-Small Cell Lung Cancer (NSCLC) Patients With Brain Metastases (GRABM-L)

Stopped early · Phase 2

Conditions studied: Non-small Cell Lung Cancer (NSCLC) With Brain Metastases

In brief

The purpose of this study is to assess the efficacy, safety, and tolerability of GRN1005 in patients with brain metastases from non-small cell lung cancer (NSCLC).

Key facts

Study ID

NCT01497665

Run by

Angiochem Inc

People needed

16

Starts

2011-11-01

Expected to finish

2013-02-01

Last updated by the study team

2019-01-22

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Univ. of California San Diego — La Jolla, California, United States
• Univ. Coloardo at Denver — Aurora, Colorado, United States
• H. Lee Moffitt Cancer Center — Tampa, Florida, United States
• Northwestern Univ. — Chicago, Illinois, United States
• Ingalls Memorial Hospital — Harvey, Illinois, United States
• Dana Farber Cancer Institute — Boston, Massachusetts, United States
• Karmanos Cancer Institute — Detroit, Michigan, United States
• Univ. of Pittsburgh Medical Center — Pittsburgh, Pennsylvania, United States
• Tennessee Oncology — Nashville, Tennessee, United States
• McGill Univ. — Montreal, Quebec, Canada

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.